TLR9

Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma

Retrieved on: 
Giovedì, Marzo 5, 2020
Bristol-Myers Squibb, Organ systems, Medicine, Ipilimumab, Medical specialties, Immune system, Melanoma, Programmed cell death protein 1, TLR9

EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the company) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its registrational trial of tilsotolimod in combination with ipilimumab in patients with anti-PD-1 refractory advanced melanoma.

Key Points: 
  • EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the company) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its registrational trial of tilsotolimod in combination with ipilimumab in patients with anti-PD-1 refractory advanced melanoma.
  • ILLUMINATE-301 is a randomized, phase 3 trial comparing the effectiveness of intratumoral tilsotolimod in combination with ipilimumab with ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, with a primary endpoint family of ORR per RECIST v1.1 and overall survival (OS).
  • Today, these refractory patients are left with few options for further treatment, paving the way for novel investigational therapies such as tilsotolimod.
  • Idera Pharmaceuticals Contacts: Jill Conwell Investor Relations & Corporate Communications Phone (484) 348-1675 [email protected] John J. Kirby Chief Financial Officer Phone (484) 348-1627 [email protected]

Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

Retrieved on: 
Lunedì, Marzo 2, 2020
Medical specialties, Branches of biology, Medicine, Vaccination, Toll-like receptors, Vaccines, TLR9, Vaccine, Hepatitis B vaccine, CpG Oligodeoxynucleotide

Dynavax is providing technical expertise and the Companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.

Key Points: 
  • Dynavax is providing technical expertise and the Companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • CpG 1018 provides a welldeveloped technology and a significant safety database, potentially accelerating the development of a COVID-19 vaccine.
  • CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (ie, Disease X).

Checkmate Pharmaceuticals Announces Data Presentations for Lead Program at The 34th Annual Meeting of The Society for Immunotherapy of Cancer

Retrieved on: 
Venerdì, Novembre 1, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Medical specialties, Clinical medicine, Cancer treatments, TLR9, Cancer immunotherapy, Society for Immunotherapy of Cancer, Immunotherapy, SITC, CMP-001, Checkmate Pharmaceuticals

Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).

Key Points: 
  • Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC).
  • CMP001 is a firstinclass CpGA Tolllike receptor 9 (TLR9) agonist that is encapsulated in a viruslike particle.
  • CMP001 is being evaluated in multiple tumor types to assess safety, activity, alternative routes of administration and combination with other immunotherapies and modalities.
  • Checkmates lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients.

Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037

Retrieved on: 
Lunedì, Ottobre 21, 2019
TLR9, United States patent law, Patent

EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No.

Key Points: 
  • EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No.
  • 10,10,463,686 entitled Immune Modulation With TLR9 Agonists For Cancer Treatment, which includes the Companys investigational therapy tilsotolimod (IMO-2125).
  • We are pleased with the continued development of tilsotolimod, including the breadth and duration of our patent portfolio, said Vincent Milano, Ideras Chief Executive Officer.
  • This new patent provides additional intellectual property coverage and demonstrates our ongoing commitment to tilsotolimod, patients living with melanoma and innovation.

Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001

Retrieved on: 
Martedì, Ottobre 1, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, TLR9, Confirmatory trial, CMP‐001, Checkmate

We look forward to the results of this clinical trial, commented Barry Labinger, President and CEO of Checkmate Pharmaceuticals.

Key Points: 
  • We look forward to the results of this clinical trial, commented Barry Labinger, President and CEO of Checkmate Pharmaceuticals.
  • (Identifier: NCT02554812)
    CMP001 is a firstinclass CpGA Tolllike receptor 9 (TLR9) agonist that is encapsulated in a viruslike particle.
  • Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Checkmates lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients.

Exicure to Present at the AACR Annual Meeting 2019

Retrieved on: 
Lunedì, Aprile 1, 2019
Health, Biotechnology, Clinical trials, Genetics, Oncology, Pharmaceutical, Research, Science, Spherical nucleic acid, TLR9, SNA

Exicure, Inc. (OTCQB:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, will present pre-clinical and clinical data for its TLR9 immune system agonist, AST-008, in two poster sessions at the AACR Annual Meeting 2019 in Atlanta, Georgia from March 29 April 03, 2019.

Key Points: 
  • Exicure, Inc. (OTCQB:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, will present pre-clinical and clinical data for its TLR9 immune system agonist, AST-008, in two poster sessions at the AACR Annual Meeting 2019 in Atlanta, Georgia from March 29 April 03, 2019.
  • On behalf of the Exicure team, we are pleased to announce these two posters which underscore the importance of Exicures SNA technology for immune therapy against cancer, said Dr. David Giljohann, Chief Executive Officer of Exicure.
  • Exicures drug, AST-008, is now enrolling patients in a Phase 1b/2 trial in patients with advanced solid tumors.
  • A second poster, to be presented by Celldex scientists, showcases data generated by Celldex Therapeutics, Inc. and Exicure through an ongoing scientific collaboration.